Has had a prior monoclonal antibody within  weeks prior to study Day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier; non-clinically significant adverse events may be considered as an exception after discussion with and approval by the principal investigator
SAFETY RUN-IN: Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
RANDOMIZED PHASE II CLINICAL TRIAL: Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody within  weeks prior to study day  or has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody =<  days prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior treatment with a monoclonal antibody within  weeks prior to the first dose of MK- or has not recovered (i.e. =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has received a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had prior monoclonal antibody therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Has had prior anticancer therapy within  weeks of study day  or has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Subjects must not have received a prior monoclonal antibody within  weeks prior to the first dose of study medication, and must have recovered (=< grade ) from adverse events related to any anti-cancer agent administered >  weeks previous to the first dose of study medication
Administration of a monoclonal antibody within  weeks prior to initiating study treatment or has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Received prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks or  half-lives, whichever is shorter, prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had prior anti-cancer monoclonal antibody within  weeks of Study Day  or who has not recovered from adverse events due to agents administered > weeks earlier
Has had a prior monoclonal antibody within  weeks or  half-lives, which ever is shorter, prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Subject has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; denosumab is allowed as long as not <  week prior to study day  and not administered on day of MK- infusion
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior monoclonal antibody within  weeks prior to study day  or individuals who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Subject has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
DOSE ESCALATION COHORT: Prior monoclonal antibody within  weeks before study day  or not recovered (? grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier; exception to this rule would be use of denosumab
DOSE EXPANSION COHORT: Prior monoclonal antibody within  weeks before study day  or not recovered (? grade  or at baseline) from AEs due to agents administered more than  weeks earlier; exception to this rule would be use of denosumab
Has had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Non-small cell lung cancer patients only: has had a prior monoclonal antibody within  weeks prior to first protocol treatment or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Prior monoclonal antibody within  weeks prior to study Day  ( weeks for RS participants) or who has not recovered (i.e. ? Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier ( weeks for RS participants).
Prior anti-cancer monoclonal antibody within  weeks prior to first dose of study drug or has not recovered from adverse effects due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody within  weeks prior to study Day  or who has not recovered (i.e., ? Grade  or at baseline) from AEs due to agents administered more than  weeks earlier.
Prior anti-cancer monoclonal antibody within  weeks prior to first dose of study drug, or not recovered from adverse effects due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study Day  or who has not recovered (i.e., ?Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody (except bevacizumab) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; wash out period for bevacizumab is  days
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had monoclonal antibody therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  at baseline; excludes alopecia and grade  neuropathy) from adverse events due to agent(s) administered more than  weeks earlier
Participant has had a prior monoclonal antibody within  weeks prior to study Day  or who has not recovered (i.e. ? Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to prior therapies
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to radiation therapy or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; denosumab is a prohibited medication on study and for  weeks prior to day 
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patient has had a prior monoclonal antibody for a noncancer therapy indication within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Has had prior monoclonal antibody therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier
Prior monoclonal antibody within  weeks before study Day , or has not recovered from adverse events due to agents administered more than  weeks earlier.
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from AEs due to agents administered more than  weeks earlier
Treatment with an anti-cancer monoclonal antibody within  weeks prior to day  or has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks before study day  or who has not recovered (i.e., =< grade  or at baseline) from AEs due to agents administered more than  weeks earlier\r\n* Note: the following will not be exclusionary: patients may have any grade alopecia or lymphopenia and still participate if other inclusion/exclusion criteria are met; patients may have grade  or  neuropathy at baseline and still participate if other inclusion/exclusion criteria are met
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior treatment with a monoclonal antibody within  weeks prior to enrollment or who has not recovered (i.e. ? Grade  or baseline grade) from adverse events due to agents administered more than  weeks earlier.
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =<, grade  or at baseline and other than alopecia) from adverse events due to agents administered more than  weeks earlier; exceptions to these criteria may be allowed at the discretion of the UNC PI for toxicities that are not expected to be exacerbated by pembrolizumab or nab-paclitaxel
Has had a prior monoclonal antibody within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
